228 related articles for article (PubMed ID: 23721786)
1. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
[TBL] [Abstract][Full Text] [Related]
2. A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.
Dranka BP; Gifford A; McAllister D; Zielonka J; Joseph J; O'Hara CL; Stucky CL; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2014 Nov; 583():159-64. PubMed ID: 25263790
[TBL] [Abstract][Full Text] [Related]
3. Homozygous mutation of the LRRK2 ROC domain as a novel genetic model of parkinsonism.
Chen ML; Wu RM
J Biomed Sci; 2022 Aug; 29(1):60. PubMed ID: 35965315
[TBL] [Abstract][Full Text] [Related]
4. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
[TBL] [Abstract][Full Text] [Related]
5. Non-motor and motor features in LRRK2 transgenic mice.
Bichler Z; Lim HC; Zeng L; Tan EK
PLoS One; 2013; 8(7):e70249. PubMed ID: 23936174
[TBL] [Abstract][Full Text] [Related]
6. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
[TBL] [Abstract][Full Text] [Related]
7. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
[TBL] [Abstract][Full Text] [Related]
8. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
[TBL] [Abstract][Full Text] [Related]
9. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
[TBL] [Abstract][Full Text] [Related]
10. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein.
Cho HJ; Liu G; Jin SM; Parisiadou L; Xie C; Yu J; Sun L; Ma B; Ding J; Vancraenenbroeck R; Lobbestael E; Baekelandt V; Taymans JM; He P; Troncoso JC; Shen Y; Cai H
Hum Mol Genet; 2013 Feb; 22(3):608-20. PubMed ID: 23125283
[TBL] [Abstract][Full Text] [Related]
12. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
[TBL] [Abstract][Full Text] [Related]
13. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity.
Gillardon F; Schmid R; Draheim H
Neuroscience; 2012 Apr; 208():41-8. PubMed ID: 22342962
[TBL] [Abstract][Full Text] [Related]
14. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
[TBL] [Abstract][Full Text] [Related]
15. Changes in matrix metalloprotease activity and progranulin levels may contribute to the pathophysiological function of mutant leucine-rich repeat kinase 2.
Caesar M; Felk S; Zach S; Brønstad G; Aasly JO; Gasser T; Gillardon F
Glia; 2014 Jul; 62(7):1075-92. PubMed ID: 24652679
[TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
[TBL] [Abstract][Full Text] [Related]
17. Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease.
Lee BD; Dawson VL; Dawson TM
Trends Pharmacol Sci; 2012 Jul; 33(7):365-73. PubMed ID: 22578536
[TBL] [Abstract][Full Text] [Related]
18. The mouse/human cross-species heterodimer of leucine-rich repeat kinase 2: possible significance in the transgenic model mouse of Parkinson's disease.
Miyajima T; Ohta E; Kawada H; Maekawa T; Obata F
Neurosci Lett; 2015 Feb; 588():142-6. PubMed ID: 25562633
[TBL] [Abstract][Full Text] [Related]
19. Targeting the cannabinoid CB2 receptor to attenuate the progression of motor deficits in LRRK2-transgenic mice.
Palomo-Garo C; Gómez-Gálvez Y; García C; Fernández-Ruiz J
Pharmacol Res; 2016 Aug; 110():181-192. PubMed ID: 27063942
[TBL] [Abstract][Full Text] [Related]
20. The pathogenic LRRK2 R1441C mutation induces specific deficits modeling the prodromal phase of Parkinson's disease in the mouse.
Giesert F; Glasl L; Zimprich A; Ernst L; Piccoli G; Stautner C; Zerle J; Hölter SM; Vogt Weisenhorn DM; Wurst W
Neurobiol Dis; 2017 Sep; 105():179-193. PubMed ID: 28576705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
